Top

Cancer Chemotherapy and Pharmacology

Published in:

01-03-2019 | Original Article

Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers

Authors: Chunhua Wang, Chaoying Hu, Dan Gao, Zirun Zhao, Xiaoping Chen, Xiao Hu, Shili Gong, Lin Li, Lan Zhang

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2019

Abstract

Purpose

Abiraterone acetate is a highly variable drug and has been approved for the treatment of patients with metastatic castration-resistant prostate cancer in many countries. This study was conducted to compare the pharmacokinetic profile between the test product (abiraterone acetate tablet) and reference product ZYTIGA® (250 mg) mainly.

Methods

To overcome the high intra-subject variability of abiraterone, a two-sequence and four-period crossover study was designed to assess bioequivalence between the two products in 32 healthy male Chinese subjects under fasting conditions. The plasma concentration of abiraterone was analyzed by a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) assay and the reference-scaled procedure was used to determine bioequivalence for the pharmacokinetics parameters.

Results

The point estimate of geometric mean ratios with 90% confidence interval (CI) of maximum observed concentration (C_max) and the area under the concentration–time curve (AUC_0t) for abiraterone in the test and reference products were 100.19% (90% CI 87.05–115.32%) and 105.99% (90% CI 96.34–116.62%), respectively, and were both within the range of 80.00–125.00%. The 95% confidence upper limit bound for \({({\bar {Y}_{\text{T}}} - {\overline {Y} _{\text{R}}})^{\text{2}}}~ - ~\theta S_{{{\text{WR}}}}^{{\text{2}}}{\text{ }}\) was − 0.1079 for C_max and was − 0.0515 for AUC_0t.

Conclusions

Bioequivalence was demonstrated between the two abiraterone acetate products. The study also confirmed high intra-subject variability, for abiraterone: coefficient of variation (CV, %) of C_max values for the test and reference products were 40.33% and 46.58%, while for AUC_0t were 24.02% and 34.16%, respectively.

Trial registration

http://www.chinadrugtrials.org.cn/: CTR20170997.

Available only for authorised users

Thakur A, Roy A, Ghosh A et al (2018) Abiraterone acetate in the treatment of prostate cancer. Biomed Pharmacother 101:211–218. https://doi.org/10.1016/j.biopha.2018.02.067 CrossRefPubMed

GLOBOCAN (2018) Cancer fact sheets: prostate cancer. http://globocan.iarc.fr/old/FactSheets/cancers/prostate-new.asp. Accessed 23 June 2018

Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in china, 2015. CA Cancer J Clin 66(2):115–132. https://doi.org/10.3322/caac.21338 CrossRefPubMed

Chen W, Sun K, Zheng R et al (2018) Cancer incidence and mortality in China, 2014. Chin J Cancer Res 30(1):1–12. https://doi.org/10.21147/j.issn.1000-9604.2018.01.01 CrossRefPubMedPubMedCentral

Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15):1513–1520. https://doi.org/10.1056/NEJMoa041318 CrossRefPubMed

Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187–1197. https://doi.org/10.1056/NEJMoa1207506 CrossRefPubMed

Al-Salama ZT (2018) Apalutamide: first global approval. Drugs 78(6):699–705. https://doi.org/10.1007/s40265-018-0900-z CrossRefPubMed

Ryan CJ, Smith MR, de Bono JS et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138–148. https://doi.org/10.1056/NEJMoa1209096 CrossRefPubMed

de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995–2005. https://doi.org/10.1056/NEJMoa1014618 CrossRefPubMedPubMedCentral

10.

US Food and Drug Administration (2018) ZYTIGA™ Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202379s024lbl.pdf. Accessed 23 June 2018

11.

Acharya M, Bernard A, Gonzalez M et al (2012) Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. Cancer Chemother Pharmacol 69(6):1583–1590. https://doi.org/10.1007/s00280-012-1865-3 CrossRefPubMedPubMedCentral

12.

Inoue K, Shishido A, Vaccaro N et al (2015) Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing. Cancer Chemother Pharmacol 75(1):49–58. https://doi.org/10.1007/s00280-014-2616-4 CrossRefPubMed

13.

European Medicines Agency (2018) Guideline on the investigation of bioequivalence. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf. Accessed 23 June 2018

14.

US Food and Drug Administration (2018) Draft guideline on bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm377465.pdf. Accessed 23 June 2018

15.

World Medical Association (WMA). Declaration of Helsinki. Ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by 64th WMA General Assembly, Fortaleza, Brazil, and (2013) https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. Accessed 23 June 2018

16.

International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2018) Guideline for good clinical principles. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2__Step_4_2016_1109.pdf. Accessed 23 June 2018

17.

China National Drug Administration (2018) Guideline for good clinical principles. http://samr.cfda.gov.cn/WS01/CL0053/24473.html. Accessed 23 June 2018

18.

Center for Drug Evaluation of CNDA (2018) Guideline on bioequivalence studies with pharmacokinetic endpoints for generic chemical drugs. http://www.cde.org.cn/zdyz.do?method=largePage&id=227. Accessed 23 June 2018

19.

US Food and Drug Administration (2018) Bioanalytical method validation guidance for industry. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070107.pdf. Accessed 23 June 2018

20.

European Medicines Agency (2018) Abiraterone tablets 250 mg product-specific bioequivalence guidance. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/03/WC500222372.pdf. Accessed 23 June 2018

21.

Chi KN, Spratlin J, Kollmannsberger C et al (2015) Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. J Clin Pharmacol 55(12):1406–1414. https://doi.org/10.1002/jcph.564 CrossRefPubMed

Title: Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers
Authors: Chunhua Wang
Chaoying Hu
Dan Gao
Zirun Zhao
Xiaoping Chen
Xiao Hu
Shili Gong
Lin Li
Lan Zhang
Publication date: 01-03-2019
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2019
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3754-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 3/2019

Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells

Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors

Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms

Severe hypersensitivity reactions to platinum compounds post-pressurized intraperitoneal aerosol chemotherapy (PIPAC): first literature report

Anti-liver cancer effect and the mechanism of arsenic sulfide in vitro and in vivo

The value of serum cystatin C in early evaluation of renal insufficiency in patients undergoing chemotherapy: a systematic review and meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer